Insmed(INSM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INSM Insmed

已收盘 09-25 16:00:00 EDT

117.83

-3.72

-3.06%

盘后117.83

+0.000.00%

19:30 EDT

最高122.90	最低115.87	成交量267.27万
今开121.87	昨收121.55	日振幅5.78%
总市值257.32亿	流通市值255.48亿	总股本2.18亿
成交额3.15亿	换手率1.23%	流通股本2.17亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INSM","market":"US","secType":"STK","nameCN":"Insmed","latestPrice":117.83,"timestamp":1790366400000,"preClose":121.55,"halted":0,"volume":2672745,"hourTrading":{"tag":"盘后","latestPrice":117.83,"preClose":117.83,"latestTime":"19:30 EDT","volume":13165,"amount":1551146.4595,"timestamp":1790379006713,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.030604689428218833,"floatShares":216823566,"shares":218381503,"eps":-4.088171,"marketStatus":"已收盘","change":-3.72,"latestTime":"09-25 16:00:00 EDT","open":121.87,"high":122.9,"low":115.87,"amount":314915832.16815,"amplitude":0.057836,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.088171,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790582400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":959832000000,"exchange":"NASDAQ","adjPreClose":121.55,"preHourTrading":{"tag":"盘前","latestPrice":121.0405,"preClose":121.55,"latestTime":"09:22 EDT","volume":648,"amount":78775.16004,"timestamp":1790342557809,"change":-0.5095,"changeRate":-0.004192,"amplitude":0.015878},"postHourTrading":{"tag":"盘后","latestPrice":117.83,"preClose":117.83,"latestTime":"19:30 EDT","volume":13165,"amount":1551146.4595,"timestamp":1790379006713,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.13081,"impliedVol":0.537,"impliedVolPercentile":0.5578},"requestUrl":"/m/hq/s/INSM","defaultTab":"news","newsList":[{"id":"1116489604","title":"FDA授予Insmed的Arikayce®补充新药申请优先审评资格，处方药用户付费法案目标行动日期定为2027年1月28日","url":"https://stock-news.laohu8.com/highlight/detail?id=1116489604","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116489604?lang=zh_cn&edition=full","pubTime":"2026-09-21 19:01","pubTimestamp":1789988490,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已正式授予Insmed公司提交的Arikayce补充新药申请优先审评资格。这一申请旨在将该药物的适应症扩展至鸟分枝杆菌复合群肺病的治疗领域。值得关注的是，FDA同时设定了《处方药用户付费法案》下的目标行动日期，即2027年1月28日。这意味着，届时监管机构将就该项申请给出最终审评结论。Insmed方面表示，将继续与FDA保持紧密沟通，全力配合审评进程，以期早日将这一潜在治疗方案带给有需要的患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","LU0889565916.HKD","LU0053671581.USD","LU0320765992.SGD","INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165307450","title":"异动解读｜Insmed盘中下跌5.04%，报118.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165307450","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165307450?lang=zh_cn&edition=full","pubTime":"2026-09-15 22:11","pubTimestamp":1789481478,"startTime":"0","endTime":"0","summary":"9月15日，Insmed盘中下跌5.04%，报118.99美元/股，成交额3750.66万美元。Insmed所在的生物科技行业中，个股普遍承压，其中Ascendis Pharma跌11.3%，Vera Therapeutics跌2.5%，Moderna跌2.22%，安进跌1.49%，艾伯维跌0.77%。Insmed是一家以人为本的生物制药公司，致力于提供一流的首创疗法，以改变患有严重疾病的患者的生活。其商业组合和临床管线专注于呼吸系统、免疫学和炎症，以及神经和其他罕见疾病三个治疗领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184589465","title":"异动解读｜Insmed盘前上涨5.87%，核心药物Brinsupri获日本厚生劳动省批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1184589465","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184589465?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:02","pubTimestamp":1787904137,"startTime":"0","endTime":"0","summary":"8月28日，Insmed盘前上涨5.87%，报120.9美元/股，成交额604.5美元。消息面上，日本厚生劳动省正式批准Insmed旗下核心药物Brinsupri用于治疗12岁及以上非囊性纤维化支气管扩张症患者。Brinsupri目前已在美国、欧洲和日本三大市场获批上市，全球商业化布局进一步完善。此前公司Q2财报显示Brinsupri全球收入达3.09亿美元，超出市场预期，公司已将全年Brinsupri收入指引上调至12.5亿至14亿美元区间，RBC维持其跑赢大盘评级及195美元目标价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Insmed盘前大涨，核心药获日本批准上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162619565","title":"日本厚生劳动省批准Brinsupri®（Brensocatib）用于治疗非囊性纤维化支气管扩张症——一种严重的慢性肺部疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=1162619565","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162619565?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:01","pubTimestamp":1787569312,"startTime":"0","endTime":"0","summary":"日本厚生劳动省正式批准Brinsupri上市，用于治疗非囊性纤维化支气管扩张症患者。这是一种严重的、进行性的慢性肺部疾病。非囊性纤维化支气管扩张症以气道永久性异常扩张为特征，患者常反复遭受肺部感染、持续咳嗽及大量痰液困扰，生活质量严重受损。Brinsupri的获批基于其临床试验数据，证实了该药物在减少急性加重发作方面的潜力。日本厚生劳动省的此项决定，意味着符合条件的患者将能够通过处方获得这一创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","BK4139","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144928856","title":"异动解读 | Insmed盘中大涨31.70%，Q2业绩大幅超预期并上调全年营收指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1144928856","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144928856?lang=zh_cn&edition=full","pubTime":"2026-08-06 21:48","pubTimestamp":1786024135,"startTime":"0","endTime":"0","summary":"Insmed今日盘中股价大涨31.70%，报约129美元，引发市场广泛关注。公司核心产品Brinsupri持续放量，第二季度实现销售额3.092亿美元，环比增长49%，成为公司最主要的收入来源，贡献近73%的季度营收。此外，公司将Brinsupri的2026年全年营收指引由此前的“至少10亿美元”上调至12.5亿至14.0亿美元区间，同时重申Arikayce全年营收指引4.5亿至4.7亿美元。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193269328","title":"异动解读｜Insmed盘中上涨30.27%，Q2业绩大幅超预期并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1193269328","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193269328?lang=zh_cn&edition=full","pubTime":"2026-08-06 21:32","pubTimestamp":1786023120,"startTime":"0","endTime":"0","summary":"8月6日，Insmed盘中上涨30.27%，报129.0美元/股，成交额1.63亿美元。消息面上，公司发布第二季度财报，业绩全面大幅超出市场预期。此外，公司将核心产品Brinsupri全年营收指引由此前的至少10亿美元上调至12.5亿至14亿美元区间，同时重申Arikayce全年营收指引4.5亿至4.7亿美元。Brinsupri自获批以来持续放量叠加TPIP管线积极临床数据，多元增长逻辑进一步得到验证。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Insmed盘中上涨30.27%，Q2业绩大幅超预期并上调全年指引","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190152110","title":"异动解读 | 二季度财报大幅超预期，Insmed盘前大涨17.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190152110","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190152110?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:16","pubTimestamp":1786014982,"startTime":"0","endTime":"0","summary":"Insmed（INSM）今日盘前股价大涨17.91%，引发市场广泛关注。消息面上，公司发布了第二季度财报，业绩全面大幅超出市场预期。数据显示，第二季度每股亏损仅为0.06美元，远好于市场预期的亏损0.73美元，超预期幅度达91.78%，较去年同期每股亏损1.70美元大幅改善96.47%；营收达4.25亿美元，超出预期的3.93亿美元约8.3%。此外，公司核心产品Brinsupri自获批以来持续放量，此前机构预计全年营收有望超10亿美元，叠加Arikayce适应症拓展及TPIP管线积极临床数据，多元增长逻辑进一步得到验证，市场信心显著增强。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136900940","title":"异动解读｜Insmed盘前上涨17.15%，Q2业绩大幅超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1136900940","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136900940?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:14","pubTimestamp":1786014868,"startTime":"0","endTime":"0","summary":"8月6日，Insmed盘前上涨17.15%，报115.13美元/股，成交额155.78万美元。消息面上，公司发布第二季度财报，业绩全面大幅超出市场预期。数据显示，Q2每股亏损仅为0.06美元，远好于市场一致预期的亏损0.73美元，超预期幅度达91.78%，较去年同期每股亏损1.70美元大幅改善96.47%；营收达4.25亿美元，超出预期的3.93亿美元约8.3%，环比上季度3.06亿美元增长显著。Insmed是一家生物制药公司，专注于呼吸系统、免疫学和炎症及神经等领域严重疾病的治疗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Insmed盘前上涨17.15%，Q2业绩大幅超预期","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122694183","title":"财报前瞻｜Insmed本季度营收预计大幅增长，机构多持建设性观点","url":"https://stock-news.laohu8.com/highlight/detail?id=1122694183","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122694183?lang=zh_cn&edition=full","pubTime":"2026-07-30 10:14","pubTimestamp":1785377642,"startTime":"0","endTime":"0","summary":"Insmed将于2026年08月06日发布最新季度财报，市场关注营收高增长与亏损收窄节奏及关键管线推进进度。公司目前主营业务亮点在于产品收入维持高毛利率结构。上季度Insmed实现营收3.06亿美元，同比增长229.62%，毛利率84.50%，归属于母公司股东的净利润为-1.64亿美元，净利率-53.46%，调整后每股收益为-0.76元，同比增长46.48%。整体而言，建设性观点强调维持对本季度营收与利润率改善的信心，并关注核心产品带来的持续放量与潜在的里程碑事件对股价的催化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Insmed本季度营收预计大幅增长，机构多持建设性观点","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192427679","title":"Insmed 安慰剂交叉组在12个月时达到与Tpip持续组相似结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1192427679","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192427679?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:04","pubTimestamp":1784199856,"startTime":"0","endTime":"0","summary":"Insmed公司公布的数据显示，在为期12个月的研究中，从安慰剂交叉至Tpip治疗的患者组，其临床结局与持续接受Tpip治疗的患者组达到了相似水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM","LU0889565916.HKD","LU0320765992.SGD","LU0053671581.USD","LU0109394709.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131986078","title":"Insmed公布曲前列尼尔棕榈酸酯吸入粉剂治疗肺动脉高压患者开放标签扩展研究的积极12个月数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1131986078","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131986078?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:03","pubTimestamp":1784199827,"startTime":"0","endTime":"0","summary":"Insmed公司公布了其曲前列尼尔棕榈酸酯吸入粉剂（TPIP）在肺动脉高压患者中进行的开放标签扩展研究的12个月积极数据。该研究目前仍在进行中，最新数据显示了持续的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","LU0053671581.USD","INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642007044","title":"Insmed(INSM)盘前上涨7.07% PAH吸入式疗法3期临床试验取得积极新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2642007044","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642007044?lang=zh_cn&edition=full","pubTime":"2026-06-11 17:04","pubTimestamp":1781168653,"startTime":"0","endTime":"0","summary":"金吾财讯 | 制药公司Insmed(INSM)盘前涨逾7%，最新报98.38美元，涨幅7.07%。消息面上，该公司新近宣布，其其用于治疗肺动脉高压(PAH)的吸入式疗法(TPIP)3期临床试验取得最新进展，目前正在持续招募受试者。该研究旨在评估每日一次吸入药物对改善成年患者日常活动能力的疗效。若该后期临床试验取得成功，将有助于Insmed实现收入来源多元化，并直接与强生、United Therapeutics等在PAH领域的行业巨头展开激烈竞争。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/YjZmMjQ4YmQ4ZjZmMDRlNTI1MzFkZTUxNzM2MjM3NjU3NDA0.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YjZmMjQ4YmQ4ZjZmMDRlNTI1MzFkZTUxNzM2MjM3NjU3NDA0.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301418","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0053671581.USD","BK4139","LU0889565916.HKD","LU0320765992.SGD","INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640683871","title":"Insmed根据纳斯达克规则向103名新员工授予激励股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2640683871","media":"环球市场播报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640683871?lang=zh_cn&edition=full","pubTime":"2026-06-04 21:16","pubTimestamp":1780578960,"startTime":"0","endTime":"0","summary":"生物制药公司Insmed Incorporated近日宣布，已根据纳斯达克上市规则第5635条，向103名新入职员工授予了激励性股权奖励。这些奖励是作为吸引人才加入公司的实质性激励条件而设立的。　　此次授予的激励股权包括97，091个限制性股票单位和购买12，850股普通股的期权，行权价格为每股106.91美元，为该股票在授予日的收盘价。根据公司此前披露的信息，截至2026年3月31日，其2025年激励计划下仍有约626，576股可供未来授予。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-04/doc-iniahaik3526954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","INSM","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104364382","title":"异动解读 | Insmed盘中大涨5.78%，RBC称抛售过度叠加富达新建仓提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1104364382","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104364382?lang=zh_cn&edition=full","pubTime":"2026-05-14 00:40","pubTimestamp":1778690455,"startTime":"0","endTime":"0","summary":"Insmed今日盘中大涨5.78%，引起了市场的广泛关注。消息面上，RBC Capital Markets发布研报指出，Insmed在第一季度财报发布后的抛售属于“过度反应”，公司核心指标表现积极。该机构维持其核心产品Brinsupri全年约13亿美元的销售预期，并保持“跑赢大盘”评级，目标价虽由220美元调整至205美元，但仍远高于当前股价。此外，富达投资披露了对Insmed的新重大持仓，机构资金的入场信号进一步提振了市场情绪。公司第一季度财报发布后，股价曾累计回撤约29%，当前分析师平均目标价仍显著高于现价，市场对前期的超跌存在修复预期，共同推动了本次股价的上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124593435","title":"异动解读 | Insmed夜盘大涨5.13%，RBC称抛售过度叠加富达新建仓提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1124593435","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124593435?lang=zh_cn&edition=full","pubTime":"2026-05-13 08:45","pubTimestamp":1778633126,"startTime":"0","endTime":"0","summary":"Insmed（股票代码：INSM）在今日夜盘交易时段出现显著上涨，涨幅达5.13%。消息面上，RBC Capital Markets发布研究报告指出，Insmed在第一季度财报发布后遭遇的抛售“过度”，公司核心业务指标表现积极，并维持其核心产品Brensupri全年约13亿美元的销售预期，同时保持“跑赢大盘”评级。此外，富达投资（FMR LLC）披露了对Insmed的新重大持仓，这一机构资金入场的信号进一步提振了市场情绪。此前，公司发布Q1财报后股价累计回撤约29%，而当前分析师平均目标价仍远高于现价，市场对前期超跌存在修复预期，共同推动了此次股价的上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159726495","title":"异动解读 | Insmed盘中大涨9.80%，RBC称抛售过度叠加富达新建仓提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1159726495","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159726495?lang=zh_cn&edition=full","pubTime":"2026-05-13 01:17","pubTimestamp":1778606271,"startTime":"0","endTime":"0","summary":"Insmed(INSM)今日盘中大涨9.80%，引起了市场的广泛关注。消息面上，RBC Capital Markets发布研报指出，Insmed在Q1财报发布后的抛售\"过度\"，公司核心指标表现积极，维持其核心产品Brinsupri全年约13亿美元的销售预期，并保持\"跑赢大盘\"评级，目标价由220美元调整至205美元。此外，富达投资（FMR LLC）披露了对Insmed的新重大持仓，机构资金入场的信号进一步提振了市场情绪。此前，公司Q1财报发布后股价累计回撤约29%，而当前分析师平均目标价仍远高于现价，市场对前期超跌存在修复预期，共同推动了此次股价的显著上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170709846","title":"异动解读 | 肺病治疗药物销售额未达预期，Insmed(INSM)盘中大跌17.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170709846","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170709846?lang=zh_cn&edition=full","pubTime":"2026-05-07 23:34","pubTimestamp":1778168062,"startTime":"0","endTime":"0","summary":"Insmed(INSM)今日盘中股价大跌17.45%，引发了市场关注。消息面上，该公司报告其肺部疾病治疗药物Arikayce第一季度销售额为9810万美元，低于分析师平均预期的1.054亿美元，这一关键产品销售未达预期是导致股价下跌的主要原因。此外，公司表示正在持续评估美国政策变化的潜在影响，这些变化可能影响其另一款肺病治疗药物Brinsupri的国际上市时间。尽管公司季度总营收3.06亿美元高于分析师预期，但核心产品Arikayce的销售表现疲软，仍对投资者信心造成了显著冲击。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149799124","title":"Insmed股价跌幅持续扩大 现跌15.6%（此前涨幅误报为跌幅的修正说明）","url":"https://stock-news.laohu8.com/highlight/detail?id=1149799124","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149799124?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:39","pubTimestamp":1778164757,"startTime":"0","endTime":"0","summary":"Insmed公司股价延续跌势并进一步下探，最新交易时段跌幅已达15.6%。此次修正系针对早前误将涨幅表述为跌幅的更正说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0053671581.USD","BK4139","LU0889565916.HKD","INSM","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141413686","title":"财报前瞻｜Insmed本季度营收预计大幅增长，机构观点偏积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1141413686","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141413686?lang=zh_cn&edition=full","pubTime":"2026-04-30 13:38","pubTimestamp":1777527514,"startTime":"0","endTime":"0","summary":"Insmed将于2026年05月07日发布新一季财报，市场聚焦营收加速与亏损收窄节奏。公司主营业务以“产品”销售为主，预计本季度收入增长将由核心产品商业化与放量驱动。现有业务中增长动能最强的仍是“产品”板块，上季度贡献收入2.64亿美元，同比增长152.62%，体量与增速均处于高位。结合一致预期，本季度营收同比增幅超过两倍，显示渠道与支付侧对产品价值认可度在提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Insmed本季度营收预计大幅增长，机构观点偏积极","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135444894","title":"Insmed研究未达主要及次要疗效终点 公司将终止HS项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1135444894","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135444894?lang=zh_cn&edition=full","pubTime":"2026-04-08 04:02","pubTimestamp":1775592132,"startTime":"0","endTime":"0","summary":"Insmed公司宣布，其最新研究未能达到预设的主要疗效终点和次要疗效终点指标。基于这一结果，公司决定终止HS项目的后续开发。\n该临床试验结果的公布，意味着Insmed在相关治疗领域的探索暂告一段落。公司表示将继续评估其他研发管线的进展，优化资源分配。\n此次研究数据的披露，为投资者和行业观察者提供了该公司研发进展的重要参考依据。市场将密切关注Insmed后续的战略调整和管线布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","LU0889565916.HKD","BK4139","LU0320765992.SGD","LU0109394709.USD","INSM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.insmed.com","stockEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":-0.0189},{"period":"3month","weight":0.1758},{"period":"6month","weight":-0.1635},{"period":"1year","weight":-0.1379},{"period":"ytd","weight":-0.3016}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.2099},{"period":"1year","weight":0.1605},{"period":"ytd","weight":0.125}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Insmed Incorporated于1999年11月29日在弗吉尼亚州联邦注册成立，其主要行政办公室均位于新泽西州桥水。Insmed是一家以人为本的生物制药公司，致力于提供一流的首创疗法，以改变患有严重疾病的患者的生活。其商业组合和临床管线专注于三个治疗领域：呼吸系统、免疫学和炎症，以及神经和其他罕见。","yearOnYearQuotes":[{"month":1,"riseRate":0.457143,"avgChangeRate":0.066603},{"month":2,"riseRate":0.4,"avgChangeRate":0.075433},{"month":3,"riseRate":0.388889,"avgChangeRate":-0.049701},{"month":4,"riseRate":0.388889,"avgChangeRate":0.041727},{"month":5,"riseRate":0.388889,"avgChangeRate":0.059695},{"month":6,"riseRate":0.527778,"avgChangeRate":0.026318},{"month":7,"riseRate":0.472222,"avgChangeRate":0.002063},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.014505},{"month":9,"riseRate":0.555556,"avgChangeRate":0.031122},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.015562},{"month":11,"riseRate":0.657143,"avgChangeRate":0.105034},{"month":12,"riseRate":0.457143,"avgChangeRate":0.040841}],"exchange":"NASDAQ","name":"Insmed","nameEN":"Insmed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Insmed(INSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Insmed(INSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Insmed,INSM,Insmed股票,Insmed股票老虎,Insmed股票老虎国际,Insmed行情,Insmed股票行情,Insmed股价,Insmed股市,Insmed股票价格,Insmed股票交易,Insmed股票购买,Insmed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Insmed(INSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Insmed(INSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}